Literature DB >> 19423475

Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.

S Ferrari1, E Palmerini, E Staals, M E Abate, A Longhi, M Cesari, A Balladelli, L Pratelli, G Bacci.   

Abstract

The influence of age and sex on chemotherapy-related toxicity was evaluated in children and adults with non metastatic osteosarcoma. treatment consisted of methotrexate (MTX, 12 g/m(2)), cisplatin (CDP 120 mg/m(2)) and doxorubicin (ADM 75-90 mg/m(2)) and high-dose ifosfamide (HDIFO). toxicity data from 1,051 courses (295 with MTX, 756 based on doxorubicin, cisplatin and high-dose ifosfamide) were analyzed. Children (4-14 yrs) and females showed a higher incidence of grade 4 neutropenia and thrombocytopenia and were more frequently hospitalized for neutropenic fever compared to adolescents and young adults (AYA, 15-19 yrs) and adults (>20-40 yrs). Delayed MTX excretion was higher in adults than AYA and children. Adults (up to 40 years) can be treated with pediatric protocols for osteosarcoma and they experience lower hematologic toxicity compared to pediatric population. further investigations on sex-related susceptibility to chemotherapy in osteosarcoma patients are recommended.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423475     DOI: 10.1179/joc.2009.21.2.205

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  5 in total

1.  A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma.

Authors:  Elizabeth Fox; Christine Busch; Alexander DeBernardo; Blair Segers; Joseph Gottschalk; Richard Womer; Naomi Balamuth; Rochelle Bagatell; Frank Balis
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-07       Impact factor: 3.333

2.  Principles and Recommendations for the Provision of Healthcare in Canada to Adolescent and Young Adult-Aged Cancer Patients and Survivors.

Authors:  Conrad Fernandez; Graeme A M Fraser; Carolyn Freeman; Eva Grunfeld; Abha Gupta; Leslie Stephen Mery; Sonja De Pauw; Brent Schacter
Journal:  J Adolesc Young Adult Oncol       Date:  2011-04       Impact factor: 2.223

Review 3.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

4.  Improvement in High-Grade Osteosarcoma Survival: Results from 202 Patients Treated at a Single Institution in Taiwan.

Authors:  Giun-Yi Hung; Hsiu-Ju Yen; Chueh-Chuan Yen; Po-Kuei Wu; Cheng-Fong Chen; Paul C-H Chen; Hung-Ta H Wu; Hong-Jen Chiou; Wei-Ming Chen
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

5.  Intra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review.

Authors:  Jeremy Lewin; Samantha Wieringa; Marnie Collins; Jayesh Desai; Lisa Orme; Senthil Lingaratnam; David M Thomas
Journal:  Clin Sarcoma Res       Date:  2013-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.